Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 02 2019
Historique:
received: 12 06 2018
accepted: 15 01 2019
entrez: 1 3 2019
pubmed: 1 3 2019
medline: 17 9 2020
Statut: epublish

Résumé

The counter-regulatory axis, Angiotensin Converting Enzyme 2, Angiotensin-(1-7), Mas receptor (ACE2/Ang-1-7/MasR), of the renin angiotensin system (RAS) is a potential therapeutic target in stroke, with Ang-(1-7) reported to have neuroprotective effects in pre-clinical stroke models. Here, an extensive investigation of the functional and mechanistic effects of Ang-(1-7) was performed in a rodent model of stroke. Using longitudinal magnetic resonance imaging (MRI) it was observed that central administration of Ang-(1-7) following transient middle cerebral artery occlusion (MCAO) increased the amount of tissue salvage compared to reperfusion alone. This protective effect was not due to early changes in blood brain barrier (BBB) permeability, microglia activation or inflammatory gene expression. However, increases in NADPH oxidase 1 (Nox1) mRNA expression were observed in the treatment group compared to control. In order to determine whether Ang-(1-7) has direct cerebrovascular effects, laser speckle contrast imaging (LSCI) was performed to measure dynamic changes in cortical perfusion following reperfusion. Delivery of Ang-(1-7) did not have any effect on cortical perfusion following reperfusion however; it showed an indication to prevent the 'steal phenomenon' within the contralateral hemisphere. The comprehensive series of studies have demonstrated a moderate protective effect of Ang-(1-7) when given alongside reperfusion to increase tissue salvage.

Identifiants

pubmed: 30816157
doi: 10.1038/s41598-019-39102-8
pii: 10.1038/s41598-019-39102-8
pmc: PMC6395816
doi:

Substances chimiques

Contrast Media 0
MAS1 protein, human 0
Neuroprotective Agents 0
Peptide Fragments 0
Proto-Oncogene Mas 0
RNA, Messenger 0
Angiotensin I 9041-90-1
NADPH Oxidase 1 EC 1.6.3.-
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Ace2 protein, rat EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
angiotensin I (1-7) IJ3FUK8MOF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3154

Subventions

Organisme : Medical Research Council
ID : MR/K501335/1
Pays : United Kingdom

Références

Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1024-33
pubmed: 20656887
Eur J Pharmacol. 2015 Feb 5;748:30-6
pubmed: 25523481
Neuropeptides. 2008 Oct-Dec;42(5-6):593-600
pubmed: 18990443
Protein Pept Lett. 2017 Nov 17;24(9):869-875
pubmed: 28758595
FASEB J. 2002 Feb;16(2):169-76
pubmed: 11818364
Neuropeptides. 2013 Oct;47(5):289-95
pubmed: 24090950
Exp Physiol. 2014 Feb;99(2):442-53
pubmed: 24142453
Br J Pharmacol. 2014 Sep;171(18):4222-32
pubmed: 24824997
Amino Acids. 2017 Oct;49(10):1733-1742
pubmed: 28744580
Exp Transl Stroke Med. 2016 Mar 01;8:2
pubmed: 26933488
Exp Physiol. 2009 Aug;94(8):937-46
pubmed: 19429641
PLoS One. 2015 Jan 24;10(1):e0116814
pubmed: 25617620
Eur J Pharmacol. 2008 May 13;585(2-3):303-12
pubmed: 18417117
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
J Biol Chem. 1989 Oct 5;264(28):16518-23
pubmed: 2777795
J Cereb Blood Flow Metab. 2009 Nov;29(11):1846-55
pubmed: 19654585
Neuropharmacology. 2014 Jun;81:134-41
pubmed: 24508710
Neuroreport. 1996 Dec 20;8(1):93-6
pubmed: 9051759
Stroke. 1989 Jan;20(1):84-91
pubmed: 2643202
Brain Res. 2008 Jan 10;1188:198-206
pubmed: 18031717
J Cereb Blood Flow Metab. 2003 Dec;23(12):1479-88
pubmed: 14663344
Neuropharmacology. 2013 Aug;71:154-63
pubmed: 23583926
J Cereb Blood Flow Metab. 2016 Feb;36(2):363-9
pubmed: 26661175
Neuroscience. 2014 Jul 25;273:39-51
pubmed: 24814023
Clin Exp Pharmacol Physiol. 2014 Mar;41(3):220-6
pubmed: 24471927
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1416-24
pubmed: 17496218
Cardiovasc Res. 2010 Aug 1;87(3):578-84
pubmed: 20200044
Clin Med (Lond). 2017 Apr;17(2):161-165
pubmed: 28365630
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
Stroke. 2017 May;48(5):1362-1368
pubmed: 28364024
Stroke. 2015 Nov;46(11):3249-59
pubmed: 26451016
Clin Sci Mol Med Suppl. 1976 Dec;3:399s-402s
pubmed: 1071653
Stroke. 2007 Nov;38(11):3045-8
pubmed: 17916768
Cardiovasc Drug Rev. 2007 Summer;25(2):162-74
pubmed: 17614938
J Cereb Blood Flow Metab. 2008 Aug;28(8):1491-501
pubmed: 18478021
J Cereb Blood Flow Metab. 2004 May;24(5):536-47
pubmed: 15129186
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Iran Biomed J. 2014;18(4):232-8
pubmed: 25326022
Stroke. 2005 Aug;36(8):1679-83
pubmed: 16020761
Neuroscience. 2005;134(1):225-31
pubmed: 15963646
J Neurochem. 2016 Jan;136(1):163-71
pubmed: 26448556
Neuropharmacology. 2014 Apr;79:550-8
pubmed: 24440367
Exp Physiol. 2011 Oct;96(10):1084-96
pubmed: 21685445
J Neurointerv Surg. 2018 Apr;10(4):351-354
pubmed: 28701298
Br J Pharmacol. 2012 Dec;167(7):1520-32
pubmed: 22817481
Brain Res. 2008 Jul 11;1219:127-35
pubmed: 18538311
Ann Biomed Eng. 2012 Feb;40(2):367-77
pubmed: 22109805
Exp Physiol. 2018 Jun;103(6):916-923
pubmed: 29663576
Stroke. 2008 Jul;39(7):2029-36
pubmed: 18436887
Neuroimage. 2006 Jan 1;29(1):38-45
pubmed: 16150612
J Hypertens. 2008 Jul;26(7):1435-45
pubmed: 18551021
Int J Stroke. 2015 Jun;10(4):553-9
pubmed: 24138577
Neuroscience. 2008 Apr 22;153(1):175-81
pubmed: 18367342
Stroke. 1996 Sep;27(9):1616-22; discussion 1623
pubmed: 8784138

Auteurs

M M C Arroja (MMC)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

E Reid (E)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

L A Roy (LA)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

A V Vallatos (AV)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

W M Holmes (WM)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

S A Nicklin (SA)

BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

L M Work (LM)

BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK. Lorraine.Work@glasgow.ac.uk.

C McCabe (C)

Glasgow Experimental MRI Centre (GEMRIC), Institute of Neuroscience & Psychology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH